Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer

Franco Lumachi, Stefano M M Basso, Alba A. Brandes, Duilio Pagano, Mario Ermani

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The aim of this study was to analyze whether a correlation exists between preoperative serum tumor markers (STM) CEA and CA 15-3, age of the patients, TNM staging, hormone receptor (ER, PgR) status, and MIB-1 proliferation index in patients who underwent surgery for primary breast cancer (BC). Patients and Methods: Data regarding a series of 255 consecutive women (median age 60 years, range 30-85) with pT1-2 BC were reviewed, while patients with confirmed pT3-4 BC were excluded. All patients underwent preoperative CEA and CA 15-3 serum levels measurement, and the removed tissue was routinely processed for the detection of ER, PgR, and MIB1 index. Results: Serum CEA and CA 15-3 measurements were above the cut-off in 44 (17.2%) and 75 (29.0%) patients, respectively, and the overall sensitivity of STM was 37.6%. A strong correlation between ER and PgR rate (R=0.77) was found. There was no relationship (p=NS) between age of the patients, size (R=0.08), MIB-1 index (R=0.11), and both ER (R=0.01) and PgR (R=0.03) rate. No linear correlation was found between both CEA and CA15-3 and the other variables, except for CA 15-3 vs. tumor size, which showed a mild (R=0.57) linear relationship. Tumor size, ER rate, and the number of positive nodes were significantly (p

Original languageEnglish
Pages (from-to)3221-3224
Number of pages4
JournalAnticancer Research
Volume24
Issue number5 B
Publication statusPublished - Sep 2004

Keywords

  • Breast cancer
  • CA 15-3
  • CEA
  • Hormone receptor
  • MIB-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer'. Together they form a unique fingerprint.

Cite this